Chlamydia Trachomatis Impact on Female Reproductive Health

Chlamydia trachomatis is the world’s most frequently reported bacterial sexually transmitted infection. In women it is often asymptomatic yet can ascend from the cervix to the upper genital tract, provoking an inflammatory response that may culminate in pelvic inflammatory disease, tubal scarring and consequent infertility, as well as heightening the risk of ectopic pregnancy. Persistent or repeated infections exacerbate tissue damage through chronic inflammation and immune-mediated pathology. Globally, the burden of chlamydial disease intersects with social determinants of health, as underserved populations experience disproportionate rates of infection and barriers to screening and treatment. Effective control hinges on early detection via sensitive molecular diagnostics, prompt antibiotic therapy, targeted screening programmes and, ultimately, a prophylactic vaccine to prevent long-term reproductive sequelae.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Chlamydia Trachomatis Impact on Female Reproductive Health publication trend

The graph below shows the total number of articles in chlamydia trachomatis impact on female reproductive health across all publications each year (not limited to Nature Index journals).

Technical terms

Pelvic inflammatory disease (PID): Infection and inflammation of the upper female genital tract, including uterus, fallopian tubes and ovaries, often leading to scarring and chronic pain.

Ectopic pregnancy: Implantation of a fertilised ovum outside the uterine cavity, most commonly within a fallopian tube, posing significant risk to maternal health.

Tubal factor infertility: Impaired fertility resulting from damage, blockage or dysfunction of the fallopian tubes, often due to prior infection or inflammation.

Seroprevalence: The proportion of individuals in a population who possess specific antibodies in their blood, indicating prior exposure to a pathogen.

Pgp3 antibody: Host immunoglobulin targeting the plasmid gene product 3 of Chlamydia trachomatis, used as a serological marker of past infection.

Nucleic acid amplification test (NAAT): A highly sensitive molecular assay that detects pathogen DNA or RNA, commonly employed for chlamydia screening.

References

1. Association between serum Chlamydia trachomatis antibody levels and infertility among reproductive-aged women in the U.S.. Frontiers in Public Health (2023).
2. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. The Lancet Infectious Diseases (2016).
3. Chlamydia trachomatis as a Current Health Problem: Challenges and Opportunities. Diagnostics (2022).